BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25247760)

  • 1. Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients.
    Xue L; Zhang WW; Ding XL; Zhang JJ; Bao JA; Miao LY
    Am J Med Sci; 2014 Dec; 348(6):448-54. PubMed ID: 25247760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
    Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
    Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms.
    Kim MG; Kim IW; Choi B; Han N; Yun HY; Park S; Oh JM
    Ann Pharmacother; 2015 Jun; 49(6):622-30. PubMed ID: 25818517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.
    Zhou H; Gao Y; Cheng XL; Li ZD
    Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):271-8. PubMed ID: 22446981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.
    Xu L; Chen H; Chen J; Han M; Huang H; Lai Y; Liu D; Liu Q; Liu T; Jiang M; Ren H; Song Y; Sun Z; Wang J; Wu D; Zhou D; Zou P; Liu K; Huang X
    J Hematol Oncol; 2018 Mar; 11(1):33. PubMed ID: 29495966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.
    Ling J; Yang XP; Dong LL; Jiang Y; Zou SL; Hu N; Chen R
    J Clin Pharm Ther; 2022 Apr; 47(4):483-492. PubMed ID: 34779003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt H; Danhof M; de Fijter H; Guchelaar HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):579-90. PubMed ID: 20354687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
    García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of polymorphism of
    Wang L; Zeng G; Li J; Luo J; Li H; Zhang Z
    Xenobiotica; 2021 Jul; 51(7):852-858. PubMed ID: 33974505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
    Kim IW; Yun HY; Choi B; Han N; Park SY; Lee ES; Oh JM
    Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
    Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
    Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients.
    Sun B; Li XY; Gao JW; Rui JZ; Guo YK; Peng ZH; Liu GL
    Ther Drug Monit; 2010 Dec; 32(6):715-22. PubMed ID: 21068646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
    Hesselink DA; van Gelder T; van Schaik RH; Balk AH; van der Heiden IP; van Dam T; van der Werf M; Weimar W; Mathot RA
    Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.